¹⁸F-FDG PET/CT as comprehensive tool in multiple myeloma

This study aimed to characterize the ¹⁸F-FDG uptake pattern in Multiple Myeloma (MM) patients, assess bone marrow involvement using MRI, and compare the diagnostic utility of ¹⁸F-FDG PET/CT against MRI. MRI was performed for anatomical localization of bone lesions. PET/CT scans were conducted using ¹⁸F-FDG. Findings from PET/CT and MRI were analyzed and compared. Statistical tests assessed sensitivity, specificity, PPV, NPV, and accuracy. No significant difference was observed in detecting bone lesions between PET/CT and MRI, with PET/CT demonstrating a sensitivity of 83.3%, specificity of 75.0%, PPV of 88.2%, NPV of 66.7%, and an accuracy of 80.8% when compared to MRI. Discordant results were observed, where PET-CT normalized earlier than MRI in post-therapy patients. No significant difference in detecting bone lesions between whole-body PET/CT and MRI in MM patients. However , PET/CT identified lesions outside MRI's field of view and extra-medullary lesions, offering an advantage over MRI. PET/CT is a valuable clinical tool for comprehensive screening of myelomatous lesions, including both medullary and extra-medullary lesions